Olezarsen, a third generation ASO also targeting apo-CIII, conjugated with the ligand N-acetylgalactosamine (GalNAc) decreases TG by ~ 60% in patients with moderate hypertriglyceridemia, with studies on patients with sHTG approaching completion. This evidence concerns the gene APOC3 and hypertriglyceridemia.